ストックスクリーナーアプリを入手
1.94
10.23%
0.18
前日終値:
$1.76
開ける：
$1.77
24時間の取引高:
144.72K
Relative Volume:
3.35
時価総額：
$71.39M
収益：
$24.38M
当期純損益:
$-53.95M
株価収益率:
-0.7854
EPS:
-2.47
ネットキャッシュフロー:
$-23.31M
1週間 パフォーマンス:
+12.79%
1か月 パフォーマンス:
-4.90%
6か月 パフォーマンス:
-59.16%
1年 パフォーマンス:
-42.09%
1日の値動き範囲:
$1.75
$2.035
1週間の範囲:
$1.61
$2.035
52週間の値動き範囲:
$1.61
$5.24
Elutia Inc Stock (ELUT) Company Profile
ELUT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ELUT
Elutia Inc
|
1.94 | 70.72M | 24.38M | -53.95M | -23.31M | -2.47 |
|
ABT
Abbott Laboratories
|
133.71 | 231.29B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
103.10 | 157.07B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
381.01 | 146.67B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
85.54 | 104.07B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.72 | 44.71B | 5.54B | 4.18B | 623.10M | 7.00 |
Elutia Inc Stock (ELUT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2020-11-02 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-11-02 | 開始されました | Cowen | Outperform |
| 2020-11-02 | 開始されました | Piper Sandler | Overweight |
| 2020-11-02 | 開始されました | Truist | Buy |
Elutia Inc (ELUT) 最新ニュース
CANTOR FITZGERALD REITERATES ELUTIA STOCK RATING WITH $7 TARGET - Investing.com
CANTOR FITZGERALD REITERATES ELUTIA STOCK RATING WITH $7 TARGET By Investing.com - Investing.com India
Elutia v. Medtronic: Delaware court rules on indemnity and insurance obligations in FiberCel lawsuit - Insurance Business America
ELUT stock touches 52-week low at $1.61 amid market challenges By Investing.com - Investing.com South Africa
ELUT stock touches 52-week low at $1.61 amid market challenges - Investing.com Australia
Elutia Inc. Strengthens Drug-Eluting Biomatrix Platform with Peer-Reviewed Publication of Novel EluPro Testing Method - marketscreener.com
Elutia announces publication of article on measuring antibiotic release - TipRanks
Elutia (ELUT) Innovates with New Antibiotic Release Method | ELUT Stock News - GuruFocus
Revolutionary Drug Testing Method Cuts Medical Device Development Time from 14 Days to Just 30 Hours - Stock Titan
FY2025 EPS Estimates for Elutia Lifted by Cantor Fitzgerald - Defense World
Lake Street Capital Has Lowered Expectations for Elutia (NASDAQ:ELUT) Stock Price - Defense World
Elutia (ELUT) Price Target Reduced by Lake Street | ELUT Stock N - GuruFocus
Elutia (ELUT) Stock: Lake Street Adjusts Price Target | ELUT Sto - GuruFocus
Elutia (ELUT) Stock: Lake Street Adjusts Price Target | ELUT Stock News - GuruFocus
Elutia (ELUT) Price Target Reduced by Lake Street | ELUT Stock News - GuruFocus
Elutia Q1 2025 slides: EluPro sales surge 84% amid overall revenue decline - Investing.com Nigeria
Elutia Inc (ELUT) Q1 2025 Earnings Call Highlights: Strategic Growth and Challenges in Transition - Yahoo Finance
Elutia Inc. Reports Strong Growth in EluPro Sales - TipRanks
Earnings call transcript: Elutia Q1 2025 beats EPS forecast, stock rises - Investing.com
SEC Form 424B5 filed by Elutia Inc. - Quantisnow
Elutia Inc Reports Q1 2025 Earnings: EPS of -$0.21 Meets Estimates, Revenue of $3.1 Million Misses Estimates - GuruFocus
Elutia Announces Strong First Quarter 2025 Financial Results Driven by 84% Sequential Growth in EluPro™ Sales - The Manila Times
Elutia Inc (ELUT) Q1 2025: Everything You Need To Know Ahead Of Earnings - GuruFocus
Renaissance Technologies LLC Sells 11,700 Shares of Elutia Inc. (NASDAQ:ELUT) - Defense World
Elutia Inc. Ends Distribution Agreement with LeMaitre - TipRanks
Elutia Inc expected to post a loss of 20 cents a shareEarnings Preview - TradingView
Aziyo Biologics (ELUT) Receives a New Rating from Lake Street - The Globe and Mail
Elutia Transitions to Direct Distribution of Its Cardiovascular Product Portfolio | ELUT Stock News - GuruFocus
Elutia (ELUT) Resumes Direct Control Over Cardiovascular Portfol - GuruFocus
Elutia Transitions to Direct Distribution of Its Cardiovascular Product Portfolio - The Manila Times
Elutia Ends LeMaitre Partnership: Strategic Shift Promises 80% Margins in $2.9M Cardiovascular Line - Stock Titan
Elutia Inc. Announces First Quarter 2025 Financial Results Release and Conference Call Details - Nasdaq
Elutia to Report First Quarter 2025 Financial Results on Thursday, May 8, 2025 - The Manila Times
Elutia to Participate in Chardan's Trending Issues in Drug Development Conference Series on April 29 | ELUT Stock News - GuruFocus
Elutia's Top Scientist Reveals Drug Development Strategy: Key Regulatory Catalysts in Focus - Stock Titan
Elutia to Participate in Chardan’s Trending Issues in Drug Development Conference Series on April 29 - TradingView
Elutia (ELUT) Begins EluPro Clinical Study to Enhance Patient Ou - GuruFocus
Elutia (ELUT) Begins EluPro Clinical Study to Enhance Patient Outcomes | ELUT Stock News - GuruFocus
Elutia Initiates EluPro™ Registry Study Designed to Generate Evidence Supporting the Use of EluPro in Real-World Clinical Practice | ELUT Stock News - GuruFocus
Elutia Initiates EluPro™ Registry Study Designed to Generate Evidence Supporting the Use of EluPro in Real-World Clinical Practice - The Manila Times
Elutia Inc. Initiates Clinical Study for EluPro™ to Enhance Cardiac Device Outcomes - Nasdaq
Elutia Begins Landmark Registry Study for Revolutionary CIED Protection Technology EluPro - Stock Titan
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Elutia (ELUT) Reports Resilience Amid Global Tariff Changes | EL - GuruFocus
Elutia Confirms No Material Impact from Global Tariffs | ELUT St - GuruFocus
Elutia unaffected by global tariffs, maintains US focus By Investing.com - Investing.com South Africa
Elutia unaffected by global tariffs, maintains US focus - Investing.com Canada
Elutia Unaffected by Global Tariffs Due to US-Based Operations - marketscreener.com
Elutia Confirms No Material Impact from Global Tariffs - The Manila Times
US-Made Medical Devices: How Elutia Dodges Global Tariff Pressures - Stock Titan
Elutia Inc May Offer & Sell Up To $50.0 Million Of Shares Of Class A Common StockSEC Filing - marketscreener.com
Elutia Inc (ELUT) 財務データ
収益
当期純利益
現金流量
EPS
0.54%
0.52%
大文字化:
|
ボリューム (24 時間):